Manufacturing Environment Decontamination for Cell and Gene Therapies: What FDA's 2026 CMC Flexibility Means for VHP

Advanced therapy medicinal products — cell therapies, gene therapies, gene-modified cell therapies — are manufactured under contamination constraints that have no parallel in conventional pharmaceutical or medical device production. The product is the cell. The manufacturing environment is not a container for a chemical reaction that can be controlled at a distance; it is the immediate context within which the biological starting material is expanded, modified, transduced, and filled. Contamination of that environment is not a process deviation that triggers batch rejection and a CAPA. It is a patient safety event — or, in the case of autologous therapies, the loss of a patient-specific product that cannot be replaced.

This contamination profile makes advanced therapy manufacturing environments among the most demanding contexts for decontamination technology. And it makes the regulatory clarity that has emerged in 2025 and 2026 — from FDA on CMC flexibility, from MHRA on decentralized manufacturing — directly consequential for how those environments are designed, qualified, and maintained.

What FDA's January 2026 CMC Flexibility Guidance Actually Covers

In January 2026, FDA's Center for Biologics Evaluation and Research (CBER) published updated Chemistry, Manufacturing, and Controls (CMC) guidance for cell and gene therapy products, extending and clarifying the flexibility framework the agency has been developing since its 2020 CBER strategic priorities identified CGT as a priority product category. The January 2026 guidance provides explicit flexibility in several areas that have historically created development bottlenecks for CGT sponsors:

Phase-appropriate CMC standards — the guidance formalizes the concept that CMC requirements scale with development phase, allowing earlier-phase studies to proceed with less-complete manufacturing characterization than would be required for a BLA. This reduces the CMC burden during Phase I/II without creating a shortcut that compromises Phase III or commercial manufacturing readiness.

Manufacturing process flexibility — the guidance acknowledges that CGT manufacturing processes evolve substantially between early development and commercial scale, and provides frameworks for managing post-approval manufacturing changes without requiring full supplemental BLA review for changes that remain within defined boundaries.

Comparability standards — for autologous therapies, where each patient's cells are a unique starting material, traditional comparability testing frameworks do not apply directly. The January 2026 guidance refines the comparability approach for autologous products, reducing the CMC barrier that has slowed some autologous CAR-T and TCR-T programs.

The commercial consequence of this flexibility is an acceleration of CGT manufacturing buildout. Sponsors who have been holding manufacturing investment pending CMC clarity are now committing capital. Contract development and manufacturing organizations (CDMOs) serving the CGT space — Lonza, Catalent, WuXi Advanced Therapies — are expanding CGT manufacturing capacity in direct response to increasing sponsor demand. Each of these facility expansions requires cleanroom qualification and decontamination program development.

MHRA's Decentralized Manufacturing Framework

In June 2025, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) published its framework for decentralized and point-of-care manufacturing of advanced therapies. The framework addresses the manufacturing model that some autologous CGT therapies require: production at or near the point of patient care, rather than at a centralized manufacturing facility.

Decentralized CGT manufacturing — in which CAR-T cells, for example, are manufactured in a hospital's own cleanroom facility rather than at a CDMO and shipped to the patient — expands the geographic footprint of CGT manufacturing to clinical settings that have not historically operated pharmaceutical-grade manufacturing environments. These settings include hospital pharmacies with GMP manufacturing suites, academic medical centers with translational manufacturing infrastructure, and emerging point-of-care manufacturing platforms.

Each decentralized manufacturing site requires its own cleanroom decontamination program. The hospital pharmacy GMP suite that processes autologous cell therapies operates under the same contamination constraints as a commercial CGT manufacturing facility — the biology is the same, the patient risk is the same, and the regulatory requirements for environmental control and decontamination are the same. The MHRA framework does not reduce those requirements; it provides a regulatory pathway for decentralized sites to demonstrate compliance. Decontamination system selection and validation is a prerequisite for that compliance demonstration.

The Contamination Profile of CGT Manufacturing

The contamination constraints of cell and gene therapy manufacturing are distinct from both conventional pharmaceutical manufacturing and medical device sterilization in ways that make the decontamination method selection decision consequential.

**The product is biologically active and cannot be terminally sterilized.** A CAR-T cell product, a viral vector for gene delivery, or a cell-seeded tissue engineering scaffold cannot be exposed to terminal sterilization conditions. The cells must remain viable; the vectors must remain infectious; the biological structures must retain their functional architecture. This eliminates every conventional terminal sterilization method — steam, EtO, gamma irradiation, electron beam — from the product sterilization toolkit. The contamination control burden falls entirely on the manufacturing environment: the cleanroom, the isolators, the biosafety cabinets, and the process equipment must be maintained at contamination levels that make terminal product sterilization unnecessary.

**Operator-product contact is direct in many processes.** Open manipulations — media exchanges, cell transfers, vector transductions — in conventional CGT manufacturing involve direct operator-environment-product contact. Every surface in the immediate processing environment is a potential contamination source. The decontamination program for that environment must address not just particulate contamination but biological contamination — bacteria, fungi, and particularly spore-forming organisms that survive conventional cleaning but are eliminated by sporicidal decontamination.

**Autologous products are irreplaceable.** For allogeneic therapies, a contaminated batch can be discarded and a replacement lot manufactured. For autologous therapies — where the starting material is a specific patient's cells, collected by apheresis, expanded and modified in a patient-specific manufacturing run, and returned to that patient — a contamination event that requires batch discard may leave the patient without treatment options. The contamination prevention imperative is correspondingly more acute.

**Regulatory frameworks require documented decontamination validation.** 21 CFR Part 1271, which governs human cells, tissues, and cellular and tissue-based products (HCT/Ps), requires that facilities maintain appropriate environmental controls to prevent contamination. FDA's Guidance for Industry on CGMP for Phase 1 Investigational Drugs and the more recent ICH Q10 pharmaceutical quality system guidance both require documented decontamination procedures for cleanroom environments. EU Annex 1 (2022 revision) Section 4.22 requires that sporicidal agents used in isolators and cleanrooms be validated — this requirement applies to CGT manufacturing environments in EU-regulated facilities.

Why VHP Is the Logical Choice for CGT Environments

VHP's suitability for CGT manufacturing environments follows from the same properties that make it suitable for pharmaceutical isolators and medical device sterilization — but the cell therapy context makes certain properties especially decisive.

**Low temperature.** VHP operates at 30–50°C. This is within the thermal tolerance of the biological materials, culture media, and specialized equipment in a CGT manufacturing environment. Steam sterilization (121–134°C) and dry heat (160–180°C) are incompatible with the materials inside an active CGT manufacturing suite. VHP is not.

**No ionizing radiation.** Gamma irradiation and electron beam, which are used for pharmaceutical cleanroom surface decontamination in some contexts, damage DNA and RNA — the active constituents of gene therapy vectors and modified cell products. VHP achieves sporicidal efficacy through oxidative chemistry at the cell wall without ionizing radiation. Genetic material in the environment is not a decontamination target for VHP.

**No residue.** Hydrogen peroxide vapor decomposes completely to water and oxygen after the aeration phase. The biological culture media, cell substrates, and process equipment surfaces in a CGT manufacturing environment are not exposed to chemical residue from a completed and fully aerated VHP cycle. This is the same property that makes VHP the preferred sterilization method for drug-device combination products and temperature-sensitive biologics.

**Vapor-phase distribution.** The vapor-phase delivery mechanism reaches all surfaces the vapor contacts — including complex geometries inside isolators, biosafety cabinets, and process equipment. This is critical in CGT manufacturing environments where the equipment geometry is complex and the consequence of a decontamination failure at a shadowed or difficult-to-reach surface is a contamination event in direct contact with the product.

**Category A regulatory recognition.** FDA's January 2024 Category A designation for VHP and ISO 22441:2022 provide the regulatory framework within which VHP sterilization and decontamination programs are documented and submitted. For CGT manufacturers preparing IND and BLA submissions, the existence of a mature, FDA-recognized validation standard for VHP simplifies the decontamination section of manufacturing descriptions. The method does not require novel justification — it is an established method with an established validation framework.

Isolator Decontamination: The Primary CGT Application

The primary VHP application in CGT manufacturing is isolator decontamination. Isolators — positive or negative pressure enclosures that provide a physical barrier between the operator and the product — are the preferred manufacturing environment for open manipulations in CGT processes. FDA's guidance on isolator technology and EU Annex 1 both recognize isolators as the highest-assurance contamination control environment for aseptic processing.

Isolator decontamination with VHP is required before each production campaign and following any contamination event. The VHP cycle — conditioning, desorption, decontamination, aeration — is executed within the closed isolator volume, achieving the sporicidal log-reduction required by the facility's contamination control strategy. The biological indicator standard for isolator VHP decontamination is Geobacillus stearothermophilus spores — the same BI organism used for steam sterilization and for VHP medical device sterilization validation under ISO 22441.

The performance qualification requirement for isolator VHP decontamination is a minimum 6-log spore reduction at worst-case locations within the isolator — locations that represent the most geometrically challenging positions for VHP contact, the surfaces most distant from the VHP inlet, or the surfaces most likely to be shadowed by installed equipment. This worst-case BI challenge approach is directly parallel to the ISO 22441 PQ methodology for medical device sterilization chambers.

For CGT manufacturers operating multiple isolator units, the parametric precision required for cycle development compounds: each isolator model, each configuration, and each installed accessory set may require its own validated cycle. The programmable parametric control that PuroGen's [SteriFlex platform](/steriflex) provides — independent control of VHP concentration, temperature, humidity, exposure time, and aeration profile — is specifically designed to support this multi-unit, multi-configuration validation challenge without requiring separate hardware for each application.

BSL-2 and BSL-3 Laboratory Decontamination

Gene therapy manufacturing frequently involves viral vectors — lentiviral, adeno-associated viral (AAV), or adenoviral — that require Biosafety Level 2 or, in some cases, Biosafety Level 3 containment during manufacturing. BSL-2 and BSL-3 facilities have specific decontamination requirements under CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidance and under the institutional biosafety frameworks that govern vector manufacturing.

VHP room decontamination is one of the validated approaches for BSL-2 and BSL-3 facility decontamination. The same four-phase cycle used for cleanroom decontamination is applied at the room level — the facility is sealed, VHP is injected to achieve sporicidal concentrations throughout the space, dwell time is maintained, and the space is aerated before re-entry. This approach is documented in the scientific literature for BSL-3 decontamination events and is used routinely in select agent facilities, biosafety cabinet decontamination, and controlled laboratory space qualification.

For CGT manufacturers who operate viral vector manufacturing in BSL-2 or BSL-3 facilities within the same campus as aseptic cell processing, VHP provides decontamination continuity across both containment levels — the same chemistry, the same four-phase cycle structure, the same BI challenge methodology — with parameters optimized for each specific application.

The Convergence of CMC Flexibility and Decontamination Validation

The January 2026 FDA CMC flexibility guidance and the MHRA decentralized manufacturing framework both accelerate CGT manufacturing deployment. They do so by reducing regulatory friction in areas that have historically slowed CMC development — phase-appropriate standards, comparability frameworks, manufacturing change management.

Neither guidance reduces the contamination control requirements that apply to CGT manufacturing environments. The biology of the product category, and the patient safety consequences of contamination events in autologous therapy manufacturing, make those requirements immovable. What the regulatory flexibility guidance changes is the path to market — the flexibility that allows sponsors to commit manufacturing investment earlier, which means cleanroom qualification and decontamination program development occur earlier in the development timeline.

The manufacturers who understand both dimensions — the regulatory flexibility that accelerates commitment, and the contamination control requirements that govern the environments those commitments produce — are designing their manufacturing infrastructure accordingly. Decontamination system selection is not a downstream procurement question in CGT manufacturing. It is a facility design decision that determines whether the contamination control program will satisfy both FDA and EU regulatory requirements across the full product lifecycle.

For CGT manufacturers evaluating their manufacturing environment contamination control strategy, the relevant resources are PuroGen's [biotech and advanced therapy industry context](/industries/biotech), the [pharma manufacturing decontamination framework](/pharma) that addresses isolator and cleanroom decontamination in regulated environments, and the [SteriFlex platform](/steriflex) specifications that define the parametric precision available for isolator decontamination cycle development.

Frequently Asked Questions

**Why can't cell and gene therapy products be terminally sterilized?**

Terminal sterilization — steam, EtO, gamma irradiation, electron beam — achieves sterility by killing all microorganisms in and on a product. Each of these methods does so through conditions (heat, toxic gas, ionizing radiation) that are incompatible with living cells and biological vectors. CAR-T cells must remain viable to exert their therapeutic function. AAV vectors must remain infectious to deliver their genetic payload. These biological requirements make terminal sterilization impossible for CGT products. The contamination control burden falls entirely on the manufacturing environment — the cleanroom, isolators, and process equipment must be maintained at contamination levels that make terminal sterilization of the final product unnecessary.

**What does EU Annex 1 (2022) require for isolator decontamination in CGT facilities?**

EU Annex 1 (2022) Section 4.22 requires that sporicidal agents used in isolators be validated — meaning the decontamination cycle must be demonstrated to achieve the target log-reduction under the worst-case conditions expected during routine use. The validation requirement includes biological indicator challenge testing at worst-case locations within the isolator. VHP is explicitly recognized as a sporicidal agent applicable to isolator decontamination in the Annex 1 technical context. The 2022 revision strengthened the sporicidal agent validation requirement relative to the prior (1997) Annex 1, making documented VHP cycle validation a regulatory expectation rather than a recommended practice.

**How does the MHRA's decentralized manufacturing framework affect decontamination program requirements?**

The MHRA framework for decentralized and point-of-care manufacturing establishes a regulatory pathway for CGT production at clinical sites rather than centralized manufacturing facilities. It does not reduce the GMP requirements for manufacturing environments at those sites — a hospital pharmacy GMP suite producing autologous CAR-T cells operates under the same environmental control and decontamination requirements as a commercial CGT manufacturing facility. What the framework changes is the regulatory route by which a decentralized site demonstrates compliance. Decontamination validation is a prerequisite for that compliance demonstration at every decentralized manufacturing site.

**What biological indicator performance is required for VHP isolator decontamination?**

The standard performance qualification target for VHP isolator decontamination is a minimum 6-log reduction of Geobacillus stearothermophilus spores at worst-case locations within the isolator. G. stearothermophilus is the most VHP-resistant sporulating organism in the biological indicator toolkit, making it the appropriate worst-case challenge for cycle development. Self-contained BIs or calibrated D-value strips with certified spore counts are placed at locations identified through cycle development as the most geometrically challenging decontamination positions. Three consecutive successful PQ runs at those positions, each achieving ≥6-log spore reduction, constitute the performance qualification for the decontamination cycle.

**How does FDA's January 2026 CMC flexibility guidance change the decontamination validation timeline for CGT sponsors?**

The January 2026 guidance does not change decontamination validation requirements — it changes the manufacturing investment timeline by providing CMC clarity that allows sponsors to commit to manufacturing infrastructure earlier in development. Earlier manufacturing commitment means earlier facility qualification, which means decontamination program development occurs earlier in the development timeline rather than at the BLA preparation stage. For sponsors who previously deferred manufacturing buildout pending CMC guidance, the January 2026 guidance removes that deferral rationale. Decontamination validation becomes a near-term deliverable rather than a late-stage activity.

**Can a single VHP system serve both isolator decontamination and room decontamination in a CGT facility?**

Yes, with appropriate system design. A VHP generator with programmable parametric control — independent control of concentration, temperature, humidity, dwell time, and aeration profile — can develop separate validated cycles for isolator decontamination and room decontamination within the same facility, using the same system hardware with application-specific cycle parameters. Each cycle is independently validated against its own worst-case BI challenge conditions. This multi-application capability on a single system platform reduces capital cost and simplifies the decontamination program's equipment qualification documentation relative to operating separate systems for each application context.